Lanean...
Dasatinib Inhibits Procoagulant and Clot Retracting Activities of Human Platelets
Tyrosine kinase inhibitors (TKI) such as the BCR-ABL inhibitor dasatinib and nilotinib are highly effective therapies for chronic myeloid leukemia (CML). However, several lines of evidence suggest that dasatinib can induce bleeding which may be due to impaired collagen-induced platelet adhesion, agg...
Gorde:
| Argitaratua izan da: | Int J Mol Sci |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6862041/ https://ncbi.nlm.nih.gov/pubmed/31683623 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20215430 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|